19 filings
8-K
DICE
DICE Therapeutics Inc
9 Aug 23
Termination of a Material Definitive Agreement
9:26am
8-K
DICE
DICE Therapeutics Inc
20 Jun 23
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
7:01am
8-K
DICE
DICE Therapeutics Inc
7 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:26pm
8-K
DICE
DICE Therapeutics Inc
11 May 23
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
4:09pm
8-K
DICE
DICE Therapeutics Inc
15 Mar 23
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
4:07pm
8-K
eexl 1gn09cw
10 Feb 23
Departure of Directors or Certain Officers
4:16pm
8-K
zilzpf4xv91 pf1xg2jf
17 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:14pm
8-K
1mzj tz9jx
9 Nov 22
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
4:11pm
8-K
5ndh5h 3q90ldkihgo8v
13 Oct 22
DICE Announces Pricing of Upsized Public Offering of Common Stock
4:07pm
8-K
fkivltuaoldwb
11 Oct 22
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17
8:02am
8-K
shz e0ghk2g6gz3ngo
11 Aug 22
DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights
4:12pm
8-K
okn4h0jx6 8g67k
28 Jun 22
Entry into a Material Definitive Agreement
4:01pm
8-K
4di h3kkyirch0
8 Jun 22
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
zldnqw 72
12 May 22
DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights
4:14pm
8-K
se8dpgrx1kp1zsl8klq
3 May 22
Regulation FD Disclosure
8:01am
8-K
mpamnltu kosiifpm8j
28 Mar 22
Departure of Directors or Certain Officers
4:15pm
8-K
fuuhb jzq1011yc2mzs6
21 Mar 22
DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
4:05pm
8-K
9vaaxt91
17 Feb 22
Regulation FD Disclosure
6:06am
8-K
xhhnr
12 Nov 21
DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights
8:05am
- Prev
- 1
- Next